PanTheryx, Inc, a US-based global medical nutrition company, and pharma major Dr. Reddy's Laboratories Ltd., on Wednesday, September 9, 2015, signed a multi-country supply and licensing agreement.
The agreement grants Dr. Reddy's Laboratories the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention 'DiaResQ' for infectious diarrhea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select Latin American markets. The company will market the product in India and Nepal under the Reliqua brand.
DiaResQ helps to promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The medicine was recently recognized in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
PanTheryx president and CEO Mark A. Braman said, "This partnership further validates DiaResQ's potential to improve the well-being and quality of life of millions of children and their families globally."
Dr. Reddy's co-chairman and CEO, G.V. Prasad, said, "Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it."